Trials / Completed
CompletedNCT05665192
A Study to Assess Real-World Patient-Reported Outcomes With Fedratinib for Myelofibrosis Post-Ruxolitinib
Real-World Clinical and Patient Reported Outcomes With Fedratinib for Myelofibrosis Post-Ruxolitinib
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 150 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine real-world patient-reported outcomes with fedratinib (FEDR) therapy for myelofibrosis (MF) in the real-world (RW) setting.
Conditions
Timeline
- Start date
- 2021-08-02
- Primary completion
- 2023-07-24
- Completion
- 2023-07-24
- First posted
- 2022-12-27
- Last updated
- 2025-04-08
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT05665192. Inclusion in this directory is not an endorsement.